We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+59.01%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$691M
AUM Growth
+$420K
(+0.06%)
Cap. Flow
-$156M
Cap. Flow
% of AUM
-22.61%
Top 10 Holdings %
Top 10 Hldgs %
51.78%
Holding
95
New
18
Increased
18
Reduced
26
Closed
27
Top Buys
| 1 |
Celcuity
CELC
|
+$23.5M |
| 2 |
Immunome
IMNM
|
+$19.8M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$14.1M |
| 4 |
Cogent Biosciences
COGT
|
+$12.1M |
| 5 |
Pfizer
PFE
|
+$10.6M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$36.8M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$30.6M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$24.8M |
| 4 |
Insmed
INSM
|
+$24.7M |
| 5 |
CDTX
Cidara Therapeutics
CDTX
|
+$21.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$11.9B
| $56.9M | 8.24% |
422,193
-117,511
| -22% | -$12.8M |
|
|
2
Cogent Biosciences
COGT
$6.72B
| $44.2M | 6.4% |
1,245,254
+430,179
| +53% | +$12.1M |
|
3
UroGen Pharma
URGN
$1.94B
| $40.7M | 5.89% |
1,738,821
+161,538
| +10% | +$3.5M |
|
|
KALV
4
DELISTED
KalVista Pharmaceuticals
KALV
| $39.2M | 5.67% |
2,427,118
+1,063,740
| +78% | +$14.1M |
|
|
5
Celcuity
CELC
$4.46B
| $37.4M | 5.41% |
375,132
+286,446
| +323% | +$23.5M |
|
6
Nuvalent
NUVL
$9.81B
| $31.3M | 4.53% |
311,430
-60,870
| -16% | -$6M |
|
7
Dianthus Therapeutics
DNTH
$5.46B
| $30.9M | 4.47% |
750,136
+75,170
| +11% | +$2.91M |
|
8
Kodiak Sciences
KOD
$2.65B
| $28.6M | 4.14% |
1,023,122
+23,122
| +2% | +$474K |
|
9
Praxis Precision Medicines
PRAX
$8.88B
| $24.3M | 3.52% |
82,465
+31,255
| +61% | +$5.82M |
|
|
10
Immunome
IMNM
$2.6B
| $24.2M | 3.5% |
+1,126,210
| New | +$19.8M |
|
11
Fractyl Health
GUTS
$144M
| $21.6M | 3.13% |
9,840,041
-759,959
| -7% | -$1.22M |
|
12
Monte Rosa Therapeutics
GLUE
$1.98B
| $16.1M | 2.33% |
1,029,066
+334,124
| +48% | +$4.5M |
|
13
Veracyte
VCYT
$4.75B
| $15.1M | 2.18% |
357,558
+121,767
| +52% | +$4.91M |
|
14
CG Oncology
CGON
$6.44B
| $15M | 2.17% |
361,158
-277,188
| -43% | -$11.5M |
|
|
15
Rhythm Pharmaceuticals
RYTM
$7.52B
| $14.6M | 2.11% |
135,950
-234,046
| -63% | -$24.8M |
|
16
Syndax Pharmaceuticals
SNDX
$2.08B
| $13.5M | 1.95% |
642,899
+179,191
| +39% | +$3.13M |
|
17
Biogen
BIIB
$29.1B
| $13.3M | 1.92% |
75,412
-5,007
| -6% | -$818K |
|
|
18
Insmed
INSM
$23.8B
| $12.4M | 1.79% |
71,256
-135,392
| -66% | -$24.7M |
|
|
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
| $11.5M | 1.66% |
458,203
+316,965
| +224% | +$8.03M |
|
20
Viridian Therapeutics
VRDN
$2.1B
| $10.8M | 1.57% |
348,569
+89,060
| +34% | +$2.44M |
|
21
Ascendis Pharma A/S
ASND
$17.6B
| $10.5M | 1.52% |
49,228
-4,326
| -8% | -$893K |
|
|
22
Pfizer
PFE
$141B
| $10.4M | 1.51% |
+419,134
| New | +$10.6M |
|
23
Benitec Biopharma
BNTC
$447M
| $9.86M | 1.43% |
731,717
+455,450
| +165% | +$6.3M |
|
24
Avalo Therapeutics
AVTX
$975M
| $9.52M | 1.38% |
524,436
-196,486
| -27% | -$3.32M |
|
25
Guardant Health
GH
$21.6B
| $9.39M | 1.36% |
+91,914
| New | +$8.22M |
|
Similar funds
BOTOTLSJU
LA
EPIMS
CFP
USAA
OMC
AIA
EBSAM